Conventional Compared with Individualized Chemotherapy for Childhood Acute Lymphoblastic Leukemia
作者： William E. Evans , Mary V. Relling , John H. Rodman , William R. Crom , James M. Boyett
DOI: 10.1056/NEJM199802193380803
关键词: Teniposide 、 Cytarabine 、 Chemotherapy 、 Internal medicine 、 Acute lymphocytic leukemia 、 Methotrexate 、 Antimetabolite 、 Medicine 、 Childhood Acute Lymphoblastic Leukemia 、 Surgery 、 Antifolate 、 General Medicine
摘要: Background The rate of clearance antileukemic agents differs by a factor 3 to 10 among children with acute lymphoblastic leukemia. We hypothesized that the outcome treatment would be improved if doses were individualized prevent low systemic exposure drugs in patients fast drug clearance. Methods stratified and randomly assigned 182 newly diagnosed leukemia postremission regimens included high-dose methotrexate teniposide plus cytarabine. these based on body-surface area (in conventional-therapy group) or rates three medications each patient individualized-treatment group). In group, increased rapid decreased very slow Results Patients who received had significantly fewer courses exposures below target range than did patien...
sci-hub.se 参考文章(24)
William E. Evans, Mary V. Relling, Clinical Pharmacokinetics-Pharmacodynamics of Anticancer Drugs Clinical Pharmacokinectics. ,vol. 16, pp. 327- 336 ,(1989) , 10.2165/00003088-198916060-00001
CM Niemeyer, RD Gelber, NJ Tarbell, M Donnelly, LA Clavell, SR Blattner, K Donahue, HJ Cohen, SE Sallan, Low-dose versus high-dose methotrexate during remission induction in childhood acute lymphoblastic leukemia (Protocol 81-01 update). Blood. ,vol. 78, pp. 2514- 2519 ,(1991) , 10.1182/BLOOD.V78.10.2514.2514
JC Barredo, TW Synold, J Laver, MV Relling, CH Pui, DG Priest, WE Evans, Differences in constitutive and post-methotrexate folylpolyglutamate synthetase activity in B-lineage and T-lineage leukemia Blood. ,vol. 84, pp. 564- 569 ,(1994) , 10.1182/BLOOD.V84.2.564.564
M V Relling, D Fairclough, D Ayers, W R Crom, J H Rodman, C H Pui, W E Evans, Patient characteristics associated with high-risk methotrexate concentrations and toxicity. Journal of Clinical Oncology. ,vol. 12, pp. 1667- 1672 ,(1994) , 10.1200/JCO.1994.12.8.1667
A J Veerman, K Hählen, W A Kamps, E F Van Leeuwen, G A De Vaan, G Solbu, S Suciu, E R Van Wering, A Van der Does-Van der Berg, High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukemia. Results of protocol ALL VI from the Dutch Childhood Leukemia Study Group. Journal of Clinical Oncology. ,vol. 14, pp. 911- 918 ,(1996) , 10.1200/JCO.1996.14.3.911
Dorothy L. Williams, Ann Harris, Kenna J. Williams, Marie Joan Brosius, Wanda Lemonds, A direct bone marrow chromosome technique for acute lymphoblastic leukemia Cancer Genetics and Cytogenetics. ,vol. 13, pp. 239- 257 ,(1984) , 10.1016/0165-4608(84)90046-3
Donald Pinkel, Kathleen Hernandez, Luis Borella, Charlene Holton, Rhomes Aur, Gregory Samoy, Charles Pratt, Drug dosage and remission duration in childhood lymphocytic leukemia. Cancer. ,vol. 27, pp. 247- 256 ,(1971) , 10.1002/1097-0142(197102)27:2<247::AID-CNCR2820270202>3.0.CO;2-C
Donald H. Mahoney, Bruce M. Camitta, Brigid G. Leventhal, Jonathan J. Shuster, Curt J. Civin, Dorothy J. Ganick, Stephen J. Lauer, C. Philip Steuber, Barton A. Kamen, Repetitive low dose oral methotrexate and intravenous mercaptopurine treatment for patients with lower risk B—lineage acute lymphoblastic leukemia. A pediatric oncology group pilot study Cancer. ,vol. 75, pp. 2623- 2631 ,(1995) , 10.1002/1097-0142(19950515)75:10<2623::AID-CNCR2820751033>3.0.CO;2-Y
Joseph A. Sinkule, William E. Evans, High-performance liquid chromatographic assay for cytosine arabinoside, uracil arabinoside and some related nucleosides Journal of Chromatography B: Biomedical Sciences and Applications. ,vol. 274, pp. 87- 93 ,(1983) , 10.1016/S0378-4347(00)84411-4
E Masson, M V Relling, T W Synold, Q Liu, J D Schuetz, J T Sandlund, C H Pui, W E Evans, Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate. Journal of Clinical Investigation. ,vol. 97, pp. 73- 80 ,(1996) , 10.1172/JCI118409